Tercica gets boost on Genentech pact

Tercica got a boost today on the news that it's partnering with Genentech on two new combinatorial therapies. The biotech, which earned less than a million dollars last year, gains a $4 million equity payment in a deal worth up to $53 million in total. Researchers will combine Tercica's Increlex and Genentech's human growth hormone Nutropin AQ in two mid-stage trials. The therapies will be tested as a therapy for short stature not associated with growth hormone deficiency and adult growth hormone deficiency. Analysts noted that the pact will resolve a licensing spat but is of uncertain value to investors.

- see this release on the pact
- check out the AP report on Tercica

Related Articles:
Settlement sends Tercica shares up. Report
FDA gives thumbs up to Tercica's first commercial drug. Report
Genentech touts pipeline prospects as doubts fester. Report
Biotech lags Pharma stocks in first half of 2007. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.